Gadobutrol
Liver Cirrhosis
Stephanie GrägerSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 73/ 100
Competitive context
48 Active assets in the Liver Cirrhosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rifaximin Post Graduate Institute of Medical Education and Research, Chandigarh | Phase 4 | BBB |
SIMVASTATIN Chang Gung Memorial Hospital | Phase 4 | BBB |
WARFARIN Kafrelsheikh University | Phase 4 | BB |
Entecavir Third Affiliated Hospital, Sun Yat-Sen University | Phase 4 | BB |
Thymosin-̑ Beijing Friendship Hospital | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Gadobutrol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →